ReviewVaccines2024
Immunogenicity, Safety and Efficacy of the Dengue Vaccine TAK-003: A Meta-Analysis.
Review in Vaccines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Dual readout RT-LAMP for rapid on-site dengue virus detection and serotyping.Microbiology spectrum · 2026Article
- Assessing the impact of intervention strategies on dengue dynamics in Shenzhen, China.PLoS neglected tropical diseases · 2026Article
- Discovery of 10-Shogaol fromJournal of agricultural and food chemistry · 2026Article
- Post-marketing safety profile of dengue vaccines CYD-TDV and TAK-003: analysis of adverse event reports from a European database.Frontiers in pharmacology · 2026Article
- Hypersensitivity reactions to dengue vaccine TAK-003 (Qdenga®) following an immunization campaign targeting children and adolescents.Revista da Sociedade Brasileira de Medicina Tropical · 2026Article
- Article
- Unraveling viral protein-host membrane interaction for dengue and Zika.Biophysical journal · 2025Article
- Review
- Review
- Dengue Vaccination: A Practical Guide for Clinicians.Vaccines · 2025Review
- Atypical dengue fever in a partially vaccinated patient: a case report.Revista do Instituto de Medicina Tropical de Sao Paulo · 2025Article
- Review
- The interaction of Orthoflavivirus nonstructural proteins 3 and 5 with human fatty acid synthase.PloS one · 2025Article
- Trends and cross-country inequalities in dengue, 1990-2021.PloS one · 2025Article
- Pathophysiology and clinical implications of dengue-associated neurological disorders.Frontiers in microbiology · 2025Review
- Exploring the Contrasts and Similarities of Dengue and SARS-CoV-2 Infections During the COVID-19 Era.International journal of molecular sciences · 2024Review
- Long term T cell response and safety of a tetravalent dengue vaccine in healthy children.NPJ vaccines · 2024Article
- TAK-003 Dengue Vaccine Safety: Evidence from a Systematic Review and Meta-analysis of Clinical Trials.Indian journal of community medicine : official publication of Indian Association of Preventive & Social MedicineReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The TAK-003 dengue vaccine was licensed in Europe in December 2022, and the official recommendations from most EU countries are still under formulation. To support policymakers, we performed a meta-analysis to quantify TAK-003's immunogenicity, efficacy and safety among seronegative and seropositive populations after the administration of one or two vaccine doses. We included trials retrieved from MEDLINE, Scopus and ClinicalTrials.gov. The outcomes were the rates of seroconversion, virologically confirmed dengue fever and serious adverse events after each vaccine dose. Data were combined using random-effect proportion or head-to-head meta-analyses. We retrieved a total of 19 datasets, including >20,000 participants. TAK-003 showed an excellent safety profile, and the immunogenicity after two doses against the four DENV serotypes was ≥90% among both adults and children/adolescents who were either seronegative or seropositive at baseline. A single dose was able to elicit a high immunogenic response among adults (≥70%) and children/adolescents (≥90%). The primary two-dose immunization course halved the risk of all types of virologically confirmed dengue fever among seropositive children/adolescents, but seronegative minors were only protected against the diseases caused by DENV-1 and DENV-2. Overall, the results support the use of TAK-003 for the prevention of dengue fever in the pediatric population of endemic countries. Uncertainties remain on the use of a single vaccine dose in non-endemic countries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.